Protara Therapeutics, Inc.
General ticker "TARA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $122.9M (TTM average)
Protara Therapeutics, Inc. follows the US Stock Market performance with the rate: 23.3%.
Estimated limits based on current volatility of 5.1%: low 6.41$, high 7.10$
Factors to consider:
- Total employees count: 33 (+22.2%) as of 2024
- Top business risk factors: Limited operating history, Program termination risk, Market competition, License dependency, Manufacturing risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.44$, 7.29$]
- 2025-12-31 to 2026-12-31 estimated range: [1.53$, 4.77$]
Financial Metrics affecting the TARA estimates:
- Positive: with PPE of -2.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -32.86 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 92.11 > 63.39
- Positive: Investing cash flow per share per price, % of 17.58 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term TARA quotes
Long-term TARA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $67.06MM | $43.61MM | $49.15MM |
| Operating Income | $-67.06MM | $-43.61MM | $-49.15MM |
| Non-Operating Income | $1.11MM | $3.19MM | $4.56MM |
| R&D Expense | $16.81MM | $24.99MM | $31.70MM |
| Income(Loss) | $-65.95MM | $-40.42MM | $-44.60MM |
| Profit(Loss)* | $-65.95MM | $-40.42MM | $-44.60MM |
| Stockholders Equity | $102.08MM | $68.32MM | $167.13MM |
| Inventory | $1.16MM | $0.00MM | $0.00MM |
| Assets | $113.29MM | $78.95MM | $181.45MM |
| Operating Cash Flow | $-26.46MM | $-37.56MM | $-35.81MM |
| Capital expenditure | $0.12MM | $0.04MM | $0.06MM |
| Investing Cash Flow | $14.95MM | $53.11MM | $19.16MM |
| Financing Cash Flow | $-0.09MM | $-0.09MM | $139.87MM |
| Earnings Per Share** | $-5.86 | $-3.57 | $-2.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.